Clinical Experience of Combined HeartWare Ventricular Assist Device and Implantable Cardioverter Defibrillator Therapy

  • SIMON PECHA
    Department of Cardiovascular Surgery University Heart Center Hamburg Germany
  • IRIS WILKE
    Department of Electrophysiology University Heart Center Hamburg Germany
  • ALEXANDER BERNHARDT
    Department of Cardiovascular Surgery University Heart Center Hamburg Germany
  • SAMER HAKMI
    Department of Cardiovascular Surgery University Heart Center Hamburg Germany
  • YALIN YILDIRIM
    Department of Cardiovascular Surgery University Heart Center Hamburg Germany
  • DANIEL STEVEN
    Department of Electrophysiology University Heart Center Hamburg Germany
  • HERMANN REICHENSPURNER
    Department of Cardiovascular Surgery University Heart Center Hamburg Germany
  • STEPHAN WILLEMS
    Department of Electrophysiology University Heart Center Hamburg Germany
  • TOBIAS DEUSE
    Department of Cardiovascular Surgery University Heart Center Hamburg Germany
  • ALI AYDIN
    Department of Electrophysiology University Heart Center Hamburg Germany

書誌事項

公開日
2014-06-24
権利情報
  • http://onlinelibrary.wiley.com/termsAndConditions#vor
DOI
  • 10.1111/jce.12455
公開者
Wiley

この論文をさがす

説明

<jats:title>HeartWare Ventricular Assist Device and Implantable Cardioverter Defibrillator</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>The HeartWare continuous flow ventricular assist device (HVAD) is used in an increasing number of heart failure patients. In those patients, ventricular arrhythmias (VAs) are common and, consequently, many patients already have an implanted implantable cardioverter defibrillator (ICD) in place or receive ICD implantation after left ventricular assist device implantation. However, limited data on feasibility and necessity of combined ICD and HVAD therapy are available. In this study we present our technical and clinical experience.</jats:p></jats:sec><jats:sec><jats:title>Methods and Results</jats:title><jats:p>Between 01/2010 and 06/2013, 41 patients received HVAD implantation. Twenty‐six HVAD patients who already had an ICD device placed prior to HVAD implantation or received ICD implantation afterwards were enrolled in this study. Peri‐ and postoperative complications as well as ICD interrogations were documented and analyzed retrospectively.</jats:p><jats:p>Mean patients age was 58.4 ± 12.6 years; 88.5% of patients were male. During mean follow‐up of 12.2 ± 8.9 months, appropriate ICD interventions occurred in 9 patients (34.6%) due to ventricular tachyarrhythmia (n = 7) or ventricular fibrillation (n = 2). An inappropriate ICD intervention was seen in 1 patient (3.9%) due to tachycardic atrial fibrillation. Patients on HVAD with a history of VAs (n = 13) had a significantly higher incidence of ICD interventions compared to patients with primary prophylactic indication for ICD (n = 13; 53.8% vs. 7.7%; P = 0.015). No disturbance of ICD function was seen after HVAD implantation.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Combined ICD and HVAD therapy was safe and feasible, without electromagnetic interference between ICD and ventricular assist device. The incidence of ICD interventions was high in patients with a history of VAs, but low in patients with ICD implantation for primary prevention.</jats:p></jats:sec>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ